Aurobindo Pharma announced that its wholly owned subsidiary, Helix Healthcare B.V, Netherlands, has on 29 August 2019 entered into an agreement with Shanghai LongJin Investment Company, China and Sveva Capitals, Hongkong to establish a Joint Venture Company in China under the name of 'Longxiang Pharma Taizhou Co.', for development, manufacturing, marketing and sale of pharmaceutical products for China excluding Taiwan, Hongkong and Macau.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
